A variant of p22(phox), involved in generation of reactive oxygen species in the vessel wall, is associated with progression of coronary atherosclerosis.
A series of pro-oxidant and antioxidant enzymes, such as the NADPH oxidase system, maintain the redox state in the vessel wall. A major component of NADPH oxidase is p22(phox), which is implicated in atherosclerosis. We prospectively studied the association of the histidine (H)(72)-->tyrosine (Y) mutation in p22(phox) with the severity and progression/regression of coronary artery disease (CAD), plasma lipid levels, clinical events, and response to treatment with fluvastatin in a well-characterized population. Genotypes were determined by polymerase chain reaction and restriction digestion with RsaI enzyme in 368 subjects in the Lipoprotein and Coronary Atherosclerosis Study (LCAS). Fasting plasma lipids and quantitative coronary angiograms were obtained at baseline and 2.5 years after randomization to fluvastatin or placebo. Subjects with CC genotype (n=157) were identified by the presence of 396-bp and 113-bp products on gel electrophoresis. Those with TT (n=39) were identified by the presence of 316-bp, 113-bp, and 80-bp products, and those with CT (n=172) by the presence of 396-bp, 316-bp, 113-bp, and 80-bp products. Baseline and final plasma levels of lipids and the baseline severity of CAD were not significantly different among the genotypes. In the placebo group, subjects with the mutation had a 3- to 5-fold greater loss in mean minimum lumen diameter (MLD) (TT: -0.15+/-0.15; CT: -0.17+/-0.26; and CC: -0.03+/-0.22 mm; P=0. 006) and lesion-specific MLD (TT: -0.15+/-0.06; CT: -0.18+/-0.03; and CC: -0.06+/-0.03 mm; P=0.038) than those without. Progression was also more (TT: 8/17 [47%]; CT: 35/73 [48%]; and CC: 17/62 [27%]) and regression less (TT: 0/17 [0%]; CT: 1/73 [1%]; and CC: 11/72 [18%]) common in those with the mutation (P=0.002). The C(242)T mutation in p22(phox), involved in maintaining the redox state in the vessel wall, is associated with progression of coronary atherosclerosis in the LCAS population.
Cahilly
C
C
Sections of Cardiology and Atherosclerosis, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Ballantyne
C M
CM
Lim
D S
DS
Gotto
A
A
Marian
A J
AJ
D000328:Adult; D000368:Aged; D000483:Alleles; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D001808:Blood Vessels / Q000378:metabolism*; D003324:Coronary Artery Disease / Q000097:blood / Q000188:drug therapy / Q000378:metabolism*; D018450:Disease Progression; D005229:Fatty Acids, Monounsaturated / Q000627:therapeutic use; D000077340:Fluvastatin; D014644:Genetic Variation; D005838:Genotype; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D008055:Lipids / Q000097:blood; D026901:Membrane Transport Proteins; D008875:Middle Aged; D009154:Mutation; D009252:NADPH Dehydrogenase / Q000235:genetics / Q000378:metabolism*; D019255:NADPH Oxidases; D010750:Phosphoproteins / Q000235:genetics / Q000378:metabolism*; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D017382:Reactive Oxygen Species / Q000378:metabolism*
D000924:Anticholesteremic Agents; D005229:Fatty Acids, Monounsaturated; D007211:Indoles; D008055:Lipids; D026901:Membrane Transport Proteins; D010750:Phosphoproteins; D017382:Reactive Oxygen Species; D000077340:Fluvastatin; D019255:NADPH Oxidases; C086986:CYBA protein, human; D009252:NADPH Dehydrogenase